A New Market, A New Catalyst: Assessing Hims & Hers' Canadian Opportunity
Hims & Hers Health expands into Canada via Livewell acquisition, targeting a large, underserved weight-loss market. Canadian entry leverages local leadership and expertise, aiming to replicate successful European expansion and accelerate subscriber growth. GLP-1 weight-loss treatments drive revenue potential but introduce margin pressure and cost volatility, creating both opportunity and structural risk.
HIMS Stock Jumps After Buyout Deal, Boosts Blood Collection Efficiency
Hims & Hers is set to acquire YourBio Health, adding bladeless microneedle tech to transform the blood collection experience.
Hims & Hers shares jump on expansion into Canada
US-based digital health company Hims & Hers Holdings Inc (NYSE:HIMS) is entering the Canadian market following its acquisition of Livewell, a Canadian telehealth platform focused on weight loss and other wellness services. The move positions Hims & Hers to launch a Canadian weight loss program in 2026, coinciding with the availability of the first generic semaglutide.
Hims & Hers Expands Care Scope as Prescription Platforms Evolve
HIMS grows its telehealth-to-prescription model with new offerings in weight loss, hormone care and diagnostics.
Here is What to Know Beyond Why Hims & Hers Health, Inc. (HIMS) is a Trending Stock
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
HIMS vs. GDRX: Which Consumer Health Stock Offers Greater Upside?
Hims & Hers and GoodRx are reshaping virtual care, but which one leads in platform strategy and patient engagement? Let's dive in.
Hims & Hers Expands Care Scope as Digital Health Platforms Evolve
HIMS expands into low testosterone and menopause care, with plans for longevity and global growth in 2026.
Hims & Hers Accelerates Its Clinician-Led, Platform-Driven Care Model
HIMS expands its connected care model with new diagnostics, hormonal health services and at-home testosterone treatments.
HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?
Most of the health care sector's headlines are dominated by Big Pharma giants. Legacy companies, including AbbVie NYSE: ABBV, Eli Lilly NYSE: LLY, Pfizer NYSE: PFE, and Merck NYSE: MRK—and their lineup of game-changing drugs—receive the lion's share of attention.
Hims & Hers Plunges 15.6% in 3 Months: Time to Hold the Stock or Sell?
HIMS faces rising regulatory strain, margin pressure and competition despite strong revenue momentum.
Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now?
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Il Makiage parent Oddity takes aim at Hims with new telehealth skincare platform Methodiq
Oddity, the maker of Il Makiage and Spoiled Child, launched its third brand Methodiq, a telehealth platform for medical skincare. Methodiq will offer 28 new products, including creams, supplements and cosmetics, that address acne, hyperpigmentation and eczema and range in price from about $29 to around $59.
